MedTrace Logo

Maternal Voice and Quantitative EEG (qEEG)

NCT05391633 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-09-15

No results posted yet for this study

Summary

A short-term randomized, blinded placebo-controlled trial, in premature infants in the neonatal intensive care unit (NICU) at 33-35 weeks post-conceptional age, of recorded maternal voice on quantitative EEG (spectral power density) as a marker of development.

Conditions

  • Prematurity
  • Development Delay
  • Premature Birth

Interventions

BEHAVIORAL

Recorded Maternal Voice

60-minute looped recording of maternal voice, played once daily for 14 total days.

BEHAVIORAL

Placebo Recording

60-minute blank recording played once daily for 14 total days.

Sponsors & Collaborators

  • University of New Mexico

    lead OTHER

Principal Investigators

  • Aaron Cardon, MD · University of New Mexico, Health Sciences Center

  • Dawn Novak, MD · University of New Mexico, Health Sciences Center

  • Meghan Groghan · University of New Mexico, Health Sciences Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
28 Weeks
Max Age
33 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2024-06-12
Completion
2024-06-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05391633 on ClinicalTrials.gov